This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Beltramino, R. Articles by Buceta, A. M. Search for Related Content PubMed PubMed Citation Articles by Beltramino, R. Articles by Buceta, A. M. Social Bookmarking                         What's this?

An Open-Label, Randomized Multicenter Study Comparing the Efficacy and Safety of Cyclo 3 Fort® Versus Hydroxyethyl Rutoside in Chronic Venous Lymphatic Insufficiency

Adolfo Penenory, MD

Ana Maria Buceta, MD

Specialist Physician in Aesthetic Phlebology, Spanish Hospital of Buenos Aires, Buenos Aires, Argentina

The present study was designed to compare the safety and efficacy of a combination of Ruscus aculeatus, hesperidin methyl chalcone, and ascorbic acid (Cyclo 3 Fort®) versus that of hydroxyethyl rutoside in treatment of chronic venous lymphatic insufficiency. This open-label, randomized multicenter study was conducted on outpatients treated for 90 days. The patients were from three different regions of Argentina. Eighty patients, men and women, 30 to 70 years of age, with symptoms of chronic venous lymphatic insuffi ciency, ie, heavy, tired, swollen, or painful legs, were enrolled and assigned to two groups: one group treated with Cyclo 3 Fort®, the other with rutoside. The symptoms were assessed at baseline, and after 30, 60, and 90 days. The patient was asked to assess subjec tive symptoms, and the physician measured the size of the affected limbs. The efficacy was rated on a 3-point scale and safety was evaluated by the number of side effects. The results show that when all patients were comparable at baseline, after 90 days, patients treated with Cyclo 3 Fort® reported more rapid and complete regression of symptoms than those in the rutoside group, a statistically significant difference (p < 0.01). Likewise, a significant reduction in affected limb size was observed in both groups but persisted after 90 days in the Cyclo 3 Fort® group only (p < 0.01). Cyclo 3 Fort® was safe and more effective than rutoside in the treatment of venous lymphatic insufficiency, and the Cyclo 3 Fort® efficacy is probably associated with its unique mechanism of action.

Angiology, Vol. 51, No. 7, 535-544 (2000)
DOI: 10.1177/000331970005100702


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?